Window-of-Opportunity Trial of Ulixertinib for MAPK-Activated Gliomas

NCT05804227 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

RECRUITING

Status

40

Enrollment

OTHER

Sponsor class

Conditions

Gliomas

Interventions

DRUG: Ulixertinib
DRUG: Ulixertinib

Sponsor

M.D. Anderson Cancer Center

Collaborators

[object Object]